IGF2BP2 and cancer: Some studies have proved that the m6A reader IGF2BP2 can be used as a post-transcriptional regulator to participate in the differentiation of cancer and cancer stem cells [118], such as hepatocellular carcinoma [119], liposarcoma [120], and glioblastoma [121].